Reneo Pharmaceuticals Inc — Company Overview, News & Financial Data
Reneo Pharmaceuticals focuses on developing oral therapies for rare genetic mitochondrial diseases, addressing significant unmet needs.
Reneo Pharmaceuticals Inc
Company profile
About Reneo Pharmaceuticals Inc
Reneo Pharmaceuticals (NASDAQ:RPHM) is focused on developing treatments for patients with rare genetic mitochondrial diseases. Their main project is REN001, an oral therapy under investigation for several indications, including primary mitochondrial myopathies and long-chain fatty acid oxidation disorders. By advancing this pipeline, Reneo aims to address significant unmet medical needs and improve the quality of life for individuals with these challenging conditions. The company is dedicated to pioneering research, ensuring rigorous clinical trials, and collaborating with stakeholders to bring transformative therapies to market. Reneo's commitment lies in creating solutions that offer hope and tangible benefits to patients suffering from these debilitating diseases.
Snapshot
-Year founded
8Employees
San Diego, United StatesHead office
Loading Map...
Global footprint
Operations
All Locations
San Diego, US
Products and/or services of Reneo Pharmaceuticals Inc
- REN001: A pioneering project focused on developing a novel treatment for primary mitochondrial myopathies, aiming to improve muscle function in affected patients.
- Advancement of therapies: Focus on research for metabolic and rare genetic disorders, utilizing scientific insights to create impactful treatment options.
- Strategic partnerships: Collaborations with academic institutions and biotech firms to enhance discovery and development of cutting-edge therapeutic solutions.
- Clinical trials management: Execution and oversight of clinical studies to assess efficacy and safety of investigational therapies, ensuring compliance with regulatory standards.
- Patient-focused initiatives: Engagement with patient communities and advocacy groups to incorporate feedback and improve treatment approaches.
- Expansion of intellectual property: Development and protection of proprietary technologies and therapeutic compounds to secure competitive advantage in the market.
Reneo Pharmaceuticals Inc executive team
- Mr. Michael G. GreyFounder & Executive Chairman
- Mr. Gregory J. FlesherPresident, CEO & Director
- Dr. Alejandro Dorenbaum M.D.Chief Medical Officer
- Ms. Jennifer P. LamSVP of Finance & Administration and Principal Financial & Accounting Officer
- Mr. Michael P. CruseChief Operating Officer
GET YOUR GRAFA EDGE NOW
Sign up free to follow this company
We'll switch on a 30-day Edge trial as a welcome gift